Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

CKD and VHD share metabolic, inflammatory, and fibrotic pathways, worsening each other's progression and complicating ...

The treatment for end-stage heart failure continues to rapidly evolve. In the area of mechanical circulatory support, next-generation artificial hearts are ...

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Jupiter Endovascular announces positive results from SPIRARE I first-in-human study presented at TCT 2025: Menlo Park, California Tuesday, October 28, 2025, 16:00 Hrs [IST] Jupite ...

Anteris Technologies ( ($AU:AVR) ) has issued an announcement. Anteris Technologies announced favorable one-year clinical outcomes for its DurAVR® ...

Antidepressants induce cardiometabolic and other physiological alterations, which vary between medications, according to a ...

This new imaging technique, when applied to humans, could both improve our understanding of the circulatory system (veins, ...

This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.The STORM-PE randomized controlled trial, presented at TCT ...

Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million ...

Medtronic plc , a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal ...